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Background: The study investigated the economic burden of vaso-occlusive crisis (VOC) among
sickle cell disease (SCD) patients, through assessment of overall utilization and costs and costs per
VOC episode (regarding the number of VOC episodes and health care setting, respectively).
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Methods: Using the Medicaid Analytic Extracts database, the first SCD-related diagnosis claim (index
claim) between June 1, 2009–December 31, 2012 was identified among eligible adults. Patients were
required to have continuous medical and pharmacy benefits for 6 months pre- and 12 months postindex. Discrete VOC claims identified within a 3-day gap were combined as a single VOC episode.
Annual all-cause and SCD-related medical resources and costs were identified and stratified by number
of VOC episodes during the 1-year follow-up period. Health care costs per VOC episode were also
examined, stratified by care setting.
Results: Enrollees included 8521 eligible patients with a mean age of 32.88 years (SD=12.21). Of
these, 66.5% had a Charlson Comorbidity index (CCI) score of 0 (no comorbidities) and 67.3%
were female. The average total medical costs were US$34 136 (median=US$12 691) annually, and
SCD accounted for 60% of the total costs (mean=US$20 206, median=US$1204). Patients with >3
episodes had the highest annual SCD-related costs (mean=US$58 950) across all settings. Health
care resource utilization (HCRU) and costs increased substantially as the number of VOC episodes
increased. This study was limited to observation of associations rather than causal inference, and by
possible coding and identification discrepancies and the restricted generalizability of the population.
Conclusions: VOC has a severe impact on medical resource use and costs among the adult SCD
population. Further research among broader study populations is needed to facilitate the reduction of
VOC episodes and thereby improve clinical and economic outcomes for SCD patients.

INTRODUCTION
Sickle cell disease (SCD) is a complex genetic blood disease in which
erythrocytes have the propensity to change into a crescent (sickle) shape.
This increases interactions with other endovascular cells and causes
endothelium dysfunction, inflammation, and vascular damage.1,2 Of
note, multi-cell adhesion between red blood cells, white blood cells,
platelets, and endothelial cells can result in painful vaso-occlusion.3–5
Vaso-occlusive crisis (VOC) is the hallmark of SCD and sometimes
the precursor to many life-threatening complications such as acute
chest syndrome (ACS), stroke, splenic sequestration, and multisystem

organ failure.6,7 Although VOC is painful and often requires immediate
medical intervention such as emergency care and hospitalization,
studies have shown that VOC episodes are also sometimes managed at
home without emergency department (ER) visits or hospitalization.8,9
As VOCs significantly impact SCD patients’ quality of life (QOL), it is
important for clinicians to minimize their number.
In addition to its serious impact on QOL, SCD and its
complications incur a significant economic burden. It is estimated
that in 2005, the mean annual expenditure for children with SCD was
US$11 702 under Medicaid coverage and US$14 772 under employersponsored insurance.10 In particular, SCD-related health care costs
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for adults rise because many are forced to rely on urgent care, as their
access to preventive and comprehensive health care is limited by a lack
of providers and reduced insurance coverage.11 In one study on costs
between 2001–2005, the per patient-month total health care costs of
patients aged 50–64 years averaged US$2562—three times that of a
group aged 0–9 years.12
SCD management is complicated as well as costly, in part due to
the many dimensions of care. For instance, prevention of infectious
diseases and SCD-related complications is necessary from early
childhood. Such preventive approaches include newborn screening,
anti-infection vaccinations, and the use of antibiotics from birth
until completion of the initial series of vaccinations for encapsulated
organisms. Also, to preempt the onset of neurologic complications,
annual transcranial doppler ultrasonography screening is used to
monitor stroke risk and assess the need for prophylactic transfusion
therapy to prevent primary strokes.13
Among SCD maintenance treatments, blood marrow transplant
(BMT), the amino acid L-glutamine (Endari™), voxelotor, and
crizanlizumab-tmca have recently been added to the established use
of blood transfusion and hydroxyurea (HU). HU has been shown to
reduce the incidence of VOC and ACS as well as decrease necessary
blood cell transfusions and overall health care resource utilization
(HCRU); nonetheless, it remains underutilized.14-18
Because of these high levels of service and resource requirements,
one of the main challenges of SCD management is HCRU, which is
driven primarily by costly ER visits and hospitalizations.19 As its onset is
often sudden and severe, VOC routinely requires urgent interventions
(such as hospital admissions and emergency care) to prevent further
life-threatening complications.13,20 Together with its contribution to
morbidity and mortality, VOC’s substantial elevation of HCRU and
costs has made VOC management an emphasis of SCD treatment
patterns.21
As there is limited evidence on the economic burden of SCD,
especially for adult patients, the purpose of this study was to provide a
comprehensive breakdown of adult SCD patient direct medical costs,
including all-cause and SCD-related HCRU and costs. Specifically, we
stratified total costs (by the number of VOC episodes) and costs per
VOC episode (by care setting) to provide a detailed examination of
the association between VOC frequency and SCD economic burden.

METHODS
Study Design
This was a retrospective cohort analysis of patient-level data extracted
from the United States Medicaid MAX databases from January 1, 2009
through December 31, 2013. The most recent 5 years of data were used
at the time of the study and data was accessed through the Centers for
Medicare and Medicaid Services (CMS).
The study included fee-for-service (FFS) patients from all available
states and Managed Care enrollees who resided in the following 14 states
with complete data: Arizona, California, Indiana, Kansas, Kentucky,
Minnesota, Nebraska, New Jersey, New Mexico, New York, Oregon,
Tennessee, Texas, and Virginia (managed care information for patients
residing elsewhere was incomplete in the CMS MAX database).22
Patient Selection
Patients were included in the study if they were aged ≥18 years and
had an SCD diagnosis in any position (ICD-9-CM codes 282.41,
282.42, 282.60-282.69) during the identification period (July 1,
2009–December 31, 2012). The date of the first observed SCD-related
diagnosis during the identification period was designated as the index
date. Patients were required to have continuous enrollment with
medical and pharmacy coverage for the 6-month baseline and ≥1 year
of follow-up after the index date, and were followed until the earliest
of disenrollment, death, or end of study. Patients who were enrolled
in a clinical trial during the study period were excluded due to unique

treatment patterns that could influence study outcomes.
Patients with VOC episodes were identified at any time after the
index date using ICD-9-CM codes (282.42, 282.62, 282.64, 282.69).
Because treatments for 1 VOC episode can be administered in multiple
settings within a given time window, discrete VOC claims within a
3-day gap were combined and recorded as a single VOC episode.

OUTCOME ASSESSMENTS
HCRU and Costs For 1 Year
Annual all-cause and SCD-related HCRU and costs for each patient
were evaluated during the 12 months after the index date. For HCRU
analysis, the length of inpatient stays and the number of visits were
computed for the fixed 1-year period (including inpatient, outpatient,
ER, outpatient hospital, ambulatory surgery center, lab, hospice, longterm care [LTC], and pharmacy department visits).
For analysis of health care costs by facility type, only FFS patients
were calculated (Managed Care cost data are unavailable in the CMS
MAX database). Costs were adjusted to 2013 US dollars using the
medical care component of the Consumer Price Index (CPI).
HCRU and costs were considered SCD-related if they were
associated with an SCD diagnosis, SCD medications (eg, opioids,
nonsteroidal anti-inflammatory drugs [NSAIDs], and hydroxyurea),
or other SCD management procedures (eg, blood transfusion).
SCD-related HCRU and costs were also stratified by number of
VOC episodes in the 1-year follow-up period. Patients were separated
into four cohorts, according to number of VOC episodes (0, 1, 2, and
≥3).
Costs Per VOC Episode
Costs per VOC episode were identified in any setting and classified by
place of service using a hierarchical order: inpatient, ER, outpatient,
office, and other. The definition of outpatient VOCs included
those in the outpatient hospital, ambulatory surgery center, nursing
facility, or long-term care settings. Office VOCs included those in
the independent clinic, federally qualified health center, state or local
public health clinic, or rural health clinic settings.
Health care costs during the VOC episodes were identified and
included the total medical costs in any setting and outpatient pharmacy
costs related to SCD treatments. Average costs per VOC episode were
calculated for all VOC episodes and for each setting of care.
Statistical Analyses
Numbers and percentages are reported for categorical variables. Mean
values and standard deviations are reported for continuous variables.

RESULTS
Patient Baseline Characteristics
This analysis included 8521 qualifying adult patients with SCD (Figure
1), most of whom were relatively young African American women with
no comorbidities. The mean age of patients was 32.9 years (SD=12.2)
and more than half (51.9%) were in the 18–30 year age group. Nearly
three-quarters (74%) were African American, followed by Hispanic
(10.1%) and unknown race (6.8%). Females accounted for 67.3% of
the patients and 66.5% had a CCI score of 0. (Table 1)
Among all eligible patients, 24.6% had ≥1 VOC requiring an
inpatient stay during the 6-month baseline period. Infectious disease
(19.74%) was the most common baseline comorbidity, followed by
asthma (10.9%), fever (9.3%), and neoplasms (7.2%). (Table 2)
For baseline SCD management, 44.8% of the patients were
prescribed antibiotics, followed by acetaminophen (44.1%), folic
acid (29.8%), opioids (28.1%), and NSAIDs (26%); 10.8% used
hydroxyurea, and 14% had a blood transfusion. Assessment of baseline
all-cause HCRU found 53.6% of the patients had ≥1 outpatient ER
visit and 29.8% had ≥1 inpatient visit. (Table 2)
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Figure 1. Patient Selection

ID: identification; SCD: sickle cell disease

Table 1. Patient Demographic Characteristics
Sickle Cell Patients* (Age ≥18)
(N = 8521)
Baseline Demographics

N/Mean

%/SD
32.88

12.21

18–30

4421

51.9%

31–45

2521

29.6%

46–64

1526

17.9%

65+

53

0.6%

Male

2790

32.7%

Female

5731

67.3%

White

534

6.3%

Black

6305

74%

Hispanic

862

10.1%

Age (Years)
Age Group

Sex

Race/Ethnicity

Other

245

2.9%

Unknown

575

6.6%

Northeast

3800

44.6%

South

2266

26.6%

West

1612

18.9%

North Central

843

9.9%

Geographic Region

* The following ICD-9-CM codes 282.41, 282.42, 282.60-282.69 were used to identify SCD patients.
Abbreviations: N, number; SD, standard deviation.
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Table 2. Baseline Clinical Characteristics and Utilization
Sickle Cell Patients (Age ≥18)
(N = 8521)
Baseline Clinical Characteristics

N/Mean

%/SD

0.65

1.25

0

5665

66.5%

1

1593

18.7%

2–3

941

11.0%

4+

322

3.8%

Patients With Baseline VOC Episodes

2097

24.6%

Baseline Number of VOC Episodes (6 months)

1.04

2.72

Neoplasms benign and malignant

617

7.2%

Seizures

393

4.6%

Asthma

928

10.9%

Upper respiratory tract infections

565

6.6%

Acute chest syndrome

233

2.7%

Infectious and parasitic diseases

1682

19.7%

Charlson Comorbidity Index (CCI) Score

Individual Comorbid Conditions*

Fever

792

9.3%

Constipation

501

5.9%

Chronic pain

418

4.9%

Iron overload

367

4.3%

Aseptic (avascular) bone necrosis

359

4.2%

Antibiotics

3819

44.8%

Acetaminophen

3756

44.1%

Baseline SCD Management
SCD Medication*

Folic acid

2542

29.8%

Opioids (narcotics)

2393

28.1%

NSAIDs

2214

26.0%

Hydroxyurea

921

10.8%

Blood transfusions

1189

14.0%

Any pharmacy visit

7266

85.3%

Any outpatient hospital visit

5992

70.3%

Any outpatient office visit

5923

69.5%

Any outpatient ER visit

4563

53.6%

Any outpatient other visit

3580

42.0%

Any lab visit

3318

38.9%

Any inpatient stay

2543

29.8%

Other SCD Management*
Baseline All-Cause Health Care Resource*

* Only individual comorbidities with ≥4% are reported.
Abbreviations: ER, Emergency room; N, number; NSAIDs, nonsteroidal anti-inflammatory drugs;
PDE-5, phosphodiesterase type 5; SD, standard deviation; VOC, vaso-occlusive crisis.
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Annual All-Cause and SCD-Related HCRU and Costs During the
Post-index Period
Among the 8521 total adult patients with SCD, 49.8% (N = 4247)
had an FFS Medicaid plan and were included in the analysis for
health care costs. The average total medical costs were US$34 136
(median=US$12 691) in 1 year and SCD accounted for 60% of the
total costs (mean=US$20 206, median=US$1204). The largest allcause medical cost driver was inpatient costs, with average annual
expenditure at US$17 535 (median=US$1590) per patient; SCD

et al.

accounted for around 87% of these inpatient costs (mean=US$15 237).
SCD also contributed to high proportions of costs in other settings
such as pharmacy (67%) and ER (68%).
The study population also utilized health care resources
frequently. Almost all the enrolled patients had ≥1 all-cause pharmacy
visit (95.2%), and 86% of these visits were related to SCD treatments.
Large proportions of the patients had ≥1 all-cause outpatient hospital
(87.4%) and outpatient office visit (83.6%), with 57% and 75% of
these visits due to SCD, respectively. (Table 3)

Table 3. Annual All-Cause and SCD-Related HCRU and Costs
Follow-Up All-Cause HCRU and Costs in the First 12 Months
Facility Type

% Patients With ≥1 Visit

Mean Costs

Median of Costs

Inpatient

56.3%

US$17 535

US$1590

Outpatient other

56.0%

US$6891

US$0

Pharmacy

95.2%

US$3898

US$0

Long-term care (LTC)

3.0%

US$2665

US$169

Outpatient hospital

87.4%

US$2081

US$0

Outpatient ER

73.3%

US$592

US$0

Outpatient office

83.6%

US$397

US$0

Hospice

0.1%

US$34

US$3577

Lab

55.5%

US$33

US$0

Ambulatory surgery center

4.5%

US$12

US$281

US$34 136

US$12 691

Total (inpatient + outpatient + LTC + pharmacy) Cost

Follow-Up SCD-Related HCRU and Costs in the First 12 Months
% Patients with ≥1 visit

Mean Costs

Median of Costs

Inpatient

42.7%

US$15 237

US$0

Pharmacy

82.0%

US$2584

US$0

Outpatient hospital

65.2%

US$723

US$0

Facility Type

Outpatient other

28.7%

US$685

US$0

Long-term Care (LTC)

1.2%

US$498

US$0

Outpatient ER

49.9%

US$402

US$0

Outpatient office

47.7%

US$64

US$0

Lab

27.1%

US$8

US$0

Ambulatory surgery center

1.7%

US$5

US$0

Hospice

0.0%

US$0

US$0

US$20 206

US$1204

Total (inpatient + outpatient + LTC + pharmacy) Cost

Note: Health care costs were examined among patients with FFS Medicaid plan.
Abbreviations: LTC, long-term care; SCD, sickle cell disease; HCRU, health care resource utilization; FFS, fee-for-service; ER, emergency department

SCD-Related Costs and HCRU Stratified by Number of VOC
Episodes
Among the 8521 enrollees, most had no VOC episode during the 1-year
follow-up period, but a large number had ≥3 episodes. Specifically,
4452 patients had no episode, 1253 had 1 episode, 570 had 2 episodes,
and 2246 had ≥3 episodes.
Regarding SCD-related HCRU, patients with ≥3 episodes had
the highest mean number of outpatient hospital visits (mean=33.25;
SD=37.02), outpatient ER visits (mean=9.12; SD=15.35), inpatient
visists (mean=4.72; SD=5.73), inpatient length of stay (mean=26.11;
SD=35.76), and pharmacy visits (mean=3.24; SD=1.26). As expected,
utilizations increased in positive correlation with the number of
episodes (eg, patients with ≥3 episodes had four times more inpatient
visits than patients with 2 episodes). (Figure 2A)

Evaluation of SCD-related costs found total costs were highest
among patients who had ≥3 episodes, with a mean of US$58 950
(SD=US$93 147). Across the 4 cohorts, the largest cost driver was
inpatient costs; the ≥3 cohort had the highest mean inpatient costs
of US$45 088 (SD=US$85 112), followed by pharmacy, outpatient
hospital, and outpatient ER costs. As with utilizations, costs increased
for patients with a higher number of VOC episodes (eg, patients with
≥3 episodes incurred 4–5 times the total costs and inpatient costs of the
2-episode cohort). (Figure 2B)
In addition, the frequency distribution of SCD-related health
care costs for patients with FFS coverage was examined. Patients with
total cost of US$0 were excluded because the actual cost might not
have been captured. The mean total cost for patients with 0 pain
crisis to ≥3 crisis ranged from US$5516 to US$62 577 during the
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12 months of follow-up. Also, the frequency distribution for the total
SCD-related health care costs also showed that patients with ≥3 crisis
incurred a maximum total health care cost of US$1 125 371. (Figure 3)
Costs Per VOC Episode by Different Places of Service
Among the 4247 total adult SCD patients with FFS Medicaid, 2316
(50.9%) had ≥1 VOC episode after the index date. A total of 40 772
VOC episodes were identified in the following settings (in hierarchical
order): 15 395 from inpatient, 14 779 from ER, 7420 from outpatient,

2365 from office, and 813 from other settings. The mean duration of
each episode was 5.5 days (SD=11).
The mean total medical cost per VOC episode was US$4861
(SD=US$14 296). The mean costs per VOC episode varied widely across
different settings, with inpatient VOCs incurring by far the highest
per-episode cost (mean=US$11 398, SD=US$21 358), followed by ER
(US$1072 [SD=US$3458]), outpatient (US$695 [SD=US$2437]),
and office settings (US$306 [SD=US$1480]). (Figure 4)

Figure 2a. SCD-related HCRU Stratified by Number of Pain Episodes in 1 Year

ER: emergency department; LOS: length of stay

Figure 2b. SCD-related Medical Costs Stratified by Number of Pain Episodes in 1 Year

ER: emergency department; LOS: length of stay
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Figure 3. Frequency Distribution for Total Healthcare Cost Among FFS SCD Patients Stratified by Number of Crisis Episodes.

Figure 4. Healthcare Costs per VOC Episode by Settings

ER: emergency room
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DISCUSSION
This study explored the medical expenditures of adult SCD patients,
detailing the breakdown of utilizations and costs not only by number
of VOC episodes but also per-episode, stratified by setting. The results
revealed the biggest cost drivers to be inpatient vistis and pharmacy,
and shed more light on the economic burden of the disease. Although
other studies have explored the economic burden of SCD, most were
conducted at the individual state level and relevant only to specific
treatments,23-25 or focused mainly on outcomes in the pediatric
population.10,26,27 This study adds real-world evidence with more
granular insight into clinical profiles and economic outcomes among
the adult SCD population at the national level.
Previous studies indicate that VOC frequency, more so than
pain duration or pain severity, is associated with increased utilization
of health services,28 and the economic burden of SCD has been
recognized for decades. Multiple studies have reported substantial
medical expenditures among various SCD populations, with the
average annual adult SCD-related costs ranging from US$11 508–
US$21 792 in 2005,29-31 which is consistent with this study’s finding
of US$20 206.
In addition, the present study showed that VOC episodes were
the primary reason for the high medical utilizations and costs among
the study population, based on the findings on the ratio of HCRU and
costs, stratified by different number of VOC episodes. As expected, the
study showed that patients with the highest VOC frequency (the ≥3
episode cohort) incurred the highest health care costs. They accounted
for 26% of the total sample, indicating that a large group of adult
SCD patients were suffering from high-frequency VOC episodes, and
this complication was inflating overall costs for the SCD population
at large.
Hence, this study confirmed a correlation between episode
frequency and HCRU and costs (the ≥3 episode cohort incurred 4–5
times more total SCD-related medical costs and inpatient costs than
the 2 episode cohort, for instance). This could reflect increases in
episode severity requiring more resources, which was further suggested
by the per-episode cost findings, as inpatient VOC episodes had high
mean costs. Moreover, the costs per VOC episode included both VOCrelated costs and all other medical costs incurred by patients with VOC
during the episode period, which more precisely reflects the real-world
medical costs associated with VOCs.
It is also important to note there are some barriers associated with
acute VOC management. These include incomplete understanding of
the underlying mechanism of vaso-occlusive pathophysiology, sparse
access to SCD experts, lack of evidence-based treatment guidelines,
and inconsistent adherence to health care provider indications.32 As
VOC has a significant impact on patients and their families, the factors
that contribute to VOC management should be re-evaluated and
brought to the table for health care experts and decision makers to
move toward more effective interventions. Also, medication like the
newly approved crizanlizumab-tmca, which has shown efficacy in the
reduction of VOC frequency in SCD patients, could be included in the
management of SCD patients.33 This may help alleviate the burden of
frequent VOCs in SCD patients.
Further, an adjunct analysis examined the frequency distribution
for the total SCD-related health care costs for FFS SCD patients. This
analysis showed that patients with frequent crises could be associated
with a huge economic burden of over US$1 million annually, as
observed in some patients with more than 3 crises in a year. However,
we cannot ascertain whether this high cost is mainly because of the
high number of crises or the severe complications associated with the
crises.
Limitations
While the study ﬁndings elucidate medical resource use and
expenditures in this population, several limitations should be noted.

The study relied on descriptive statistical analysis of outcomes,
which requires caution in drawing conclusions from cohort
comparisons, as these results are trends without direct experimental
testing, such as randomized controlled trials, and therefore imply only
correlation, not causation. Moreover, claims data analysis has its own
limitations. For example, the data and corresponding outcomes may
be affected by administrative diagnosis coding errors, codes entered
as rule-out criteria and not actual indications of disease presence, and
deliberate misdiagnoses to justify claims for off-label prescriptions.
Another limitation of the study is that in order to capture all SCD
patients including those with low health care utilizations, patients with
≥1 SCD diagnosis in any setting were identified as SCD patients; this
might have inadvertently included some non-SCD patients due to
coding discrepancies. Although this study shows a large proportion of
patients had high VOC frequency, we believe there is underreporting of
the true number of SCD patients who experienced VOC and frequency
of the VOC because home-managed VOCs were not capturable in the
dataset used for this study.
In addition, the dataset was from 2009–2013 and real-world
clinical management of SCD may have changed since the end of the
study period.
The dataset also presented another limitation specific to this study.
As the target was HCRU and costs by facilities, only FFS patients were
included in the analysis because costs for Managed Care enrollees are
not recorded in the Medicaid MAX dataset. This reduced the sample
size and limited the generalizability of the study outcomes to other
populations.
Notwithstanding these limitations, the study does lay the
groundwork for further research that can put the analysis into more
specific statistical models and examine how the economic outcomes
are related to the reduction of VOC episodes, controlling for covariates
such as patient demographics and clinical characteristics.

CONCLUSIONS
The study found VOC episodes are associated with significant economic
burden among patients with SCD, as they led to higher frequencies
of inpatient utilizations, which were the largest cost driver among
the study population. Moreover, HCRU and costs were closely and
positively associated with the number of VOC episodes. In particular,
among patients who had 3 or more VOC episodes per year, those
episodes accounted for over 90% of the SCD-related inpatient visits
and costs. Thus, VOC frequency can be seen as a strong indicator for
medical resource use and expenditures. These findings warrant future
investigations among broader study populations with more sensitive
analysis, and ultimately may help clinicians reduce VOCs and thereby
mitigate the overall clinical and economic burden of SCD.
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